Anders Krog Vistisen

Medicine and Dentistry

1. Patient 100%
2. Radiation Therapy 60%
3. Follicular Lymphoma 60%
4. Therapeutic Procedure 45%
5. Chemotherapy 40%
6. Fluorodeoxyglucose F 18 36%
7. Lymphoma 33%
8. Niraparib 30%
9. Positron Emission Tomography 30%
10. Bevacizumab 30%
11. Platinum 30%
12. Venous Thromboembolism 30%
13. Recurrent Ovarian Cancer 30%
14. Radiation Oncology 30%
15. Patient with Cancer 30%
16. Analysis 26%
17. Follow up 22%
18. Malignant Neoplasm 20%
19. Diseases 18%
20. Death 17%
21. Recurrent Disease 15%
22. Hazard Ratio 15%
23. Cancer Types 15%
24. Kaplan Meier Method 13%
25. Overall Survival 9%
26. Inpatient 9%
27. Anticoagulation 9%
28. Cumulative Incidence 9%
29. Progression Free Survival 8%
30. Incidence 7%
31. Positron Emission Tomography-Computed Tomography 6%
32. Systemic Therapy 6%
33. PET-CT 6%
34. Biopsy 6%
35. Patient Selection 5%
36. Prophylaxis 5%
37. Pancreas Cancer 5%
38. Lung Cancer 5%
39. Thromboprophylaxis 5%
40. Equivalent Dose 5%
41. Health 5%
42. Hepatobiliary Cancer 5%
43. Risk Assessment 5%
44. Female Genital Tract Cancer 5%